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Introduction
I
n spite of the availability of a highly effective 
vaccine,  approximately  one  third  of  the 
world’s population has serological findings of past 
or present infection with hepatitis B virus (HBV); 
and globally, over 350 million people are currently 
chronically infected. The spectrum of disease and the 
natural history of chronic HBV infection is diverse 
and variable, ranging from inactive-carrier state to 
progressive chronic hepatitis, which may evolve to 
cirrhosis and hepatocellular carcinoma (HCC) (1). 
Two different types of drugs can be used in the 
treatment of chronic hepatitis B (CHB): interferon 
alpha and nucleoside/nucleotide analogues (NUCs). 
NUCs for HBV therapy belong to three subclasses: 
L-nucleosides,  i.e.  lamivudine  (LAM),  telbivudine 
(LdT),  and  emtricitabine  (FTC),  deoxyguanosine 
analogues, i.e. entecavir (ETV) and acyclic nucleoside 
phosphonates,  i.e.  adefovir  (ADV)  and  tenofovir 
(TDF). LAM, LdT, ETV, ADV, TDF and FTC have 
been approved in Europe, the United States, and 
most Asian and Latin American countries for HBV 
treatment (1, 2).
The emergence of mutations should be expect ed 
from HBV genome characteristics. The major causes 
of drug resistance include viral factors such as the 
kinetics of viral production and clearance; lack of a 
proofreading mechanism during reverse transcription, 
which creates a large HBV quasispecies pool, and 
the replication fitness of the viral quasispecies (3, 4). 
However, a major concern with NUC treatment is 
the selection of antiviral – resistant mutations. Long-
term  therapy  with  NUCs,  especially,  is  associated 
with an increased risk of the development of drug 
resistance (5, 6). Mutations selected under NUCs can 
be split into two groups : those that cause resistance 
that sometimes leads to a decreased viral fitness, and 
compensatory  mutations,  which  partially  or  fully 
restore the level of viral fitness (7, 8).
* Correspondence:
Murat Sayan, Ph.D.
Clinical Laboratory, Faculty of Medicine, Umuttepe Kampus, 
University of Kocaeli, 41340, İzmit – Kocaeli, Turkey.
Tel: +90 262 303 8571
Fax: +90 262 303 8085
E-mail: sayanmurat@hotmail.com
Received:  21 Nov 2009                  Revised:  11 Jan 2010 
Accepted:  14 Jan 2010
Hepat Mon 2010; 10 (1): 42-47
Entecavir (ETV) is a potent nucleoside analogue against hepatitis B virus (HBV). Because of development of ETV resis-
tance requires at least three amino acid substitutions in HBV polymerase (pol) gene, emergence of ETV resistance is rare 
(~1%) in nucleoside-naive patients after up to 5 years of treatment. However, it has been suggested that lamivudine 
(LAM) therapy can preselect for HBV variants associated with resistance to ETV treatment. ETV resistance increased to 
51% of patients after 5 years of ETV treatment in LAM refractory patients. The diagnosis of ETV resistance in chronic 
hepatitis B patients, mainly based on four types of molecular assays: direct sequencing, line probe assay, clonal analysis, 
and restriction fragment length polymorphism (RFLP) analysis. The applications of other assays are currently more spe-
cialized, and their use is more limited. The utility of these assays and their performance characteristics are reviewed be-
low. Briefly, the monitoring of drug-resistant variants is important in the elucidation of the prevalence and mechanisms 
of resistance development and for the more effective management of treatment options. 
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Entecavir (Baraclude)
ETV,  a  novel  carbocyclic  analogue  of  2’  - 
deoxyguanosine, inhibits HBV replication at three 
different  stages:  (1)  the  priming  of  HBV  DNA 
polymerase,  (2)  the  reverse  transcription  of  the 
negative-strand  HBV  DNA  from  the  pregenomic 
RNA, and  (3) the synthesis of the positive-strand 
HBV DNA. It was approved in 2005 in USA and in 
2006 in Europe for naïve and LAM-resistant chronic 
hepatitis B treatment (9). ETV has been shown to 
have  more  potent  antiviral  activity  than  LAM  or 
ADV in head-to-head comparison studies (10, 11). 
Entecavir Resistance
ETV resistance was first identified in two patients 
with LAM-resistant strains, who experienced virologic 
breakthrough after more than 1 year of ETV therapy 
(12). Preliminary data indicate that ETV resistance 
increased to 51% of LAM-refractory patients after 
5 years of ETV treatment (13, 14). More importantly, 
ETV resistance is rare (~1%) in nucleoside- naive 
patients after up to 5 years of treatment (Table 1) 
(15). 
Resistance  to  ETV  appears  to  occur  through 
a  two  –  hit  mechanism  with  initial  selection  of 
rt  M204V/I  mutation  followed  by  amino  acid 
subtitutions at rtT184, rtS202, or rtM250 (Table 1) 
(12). Patients who had previous resistance to LAM 
have lower treatment response and higher resistance 
rates, because only one or two additional mutations 
in the HBV polymerase (pol) gene are required for 
the  development  of  ETV  resistance,  in  contrast 
to  three  mutations  required  in  treatment-naive 
patients.  Moreover,  LAM-resistance  substitutions 
are  necessary  for  the  development  of  an  ETV-
resistant mutant (16). However, some compensatory 
mutations, such as rtV173L, rtL180M occurring in 
ETV therapy, help to restore the replication efficiency 
of the mutant virus (17). 
Some specific mutations in the HBV pol region 
are  associated  with  multidrug  failure.  A  recent 
example includes rtA181T + rtI233V + rtN236T + 
rtM250L. It is important to note that rtI233V and 
rtM250L (in domain E, related to ETV) substitutions 
do  not  confer  significant  drug  resistance,  nor  do 
they significantly reduce replication capacity in the 
absence of selection pressure, but appear to act to 
compensate  for  the  replication  defects  associated 
with multidrug resistance (18).
 
Genotypic Resistance
Genotypic  resistance  is  generally  defined  by 
revelation  of  viral  populations  characterized  by 
amino acid substitutions in the HBV pol gene that 
have been shown to confer resistance to antiviral 
drugs  by  in-vitro  phenotypic  assays  (19).  These 
Table 1. Cumulative incidence of drug resistant HBV with lamivudine and entecavir (1, 7, 12-15, 18, 39).
  Lamivudine Entecavir Entecavir
Rate of genotypic 
resistance (year) Treatment naive  Treatment naive Lamivudine resistance
1 24 % 0,2 % 6 %
2 38 % 0,5 % 15 %
3 49 % 1,2 % 36 %
4 67 % 1,2 % 46 %
5 70 % 1,2 % 51 %
Major mutations 
conferring resistance
rtV173L, 
rtL180M, 
rtA181V/T, rtM204V/I/S
rtI169T, rtT184S/A/I/L/G/C/M, 
rtS202C/I/G, rtM250I/V
(with rtL180M + rtM204V/I)
rtL180M + rtM204V/I 
± rtI169T ± rtV173L ± rtM250I/V
rtL180M + rtM204V/I 
± rtT184S/A/I/L/G/C/M, ± 
rtS202C/I/G
Cross resistance
Adefovir 
(rtA181V/T)
Telbivudine 
(rtM204/I)
Entecavir (intermediate) 
(rtL180M + rtM204V/I)
Emtricitabine 
(rtV173L, rtL180M, rtM204V/I)
Lamivudine 
(rtM204V/I/S ± rtV173L ± 
rtL180M)
Telbivudine 
(rtM204/I)
Emtricitabine 
(rtV173L, rtL180M, rtM204V/I)
Lamivudine 
(rtM204V/I/S ± rtV173L ± 
rtL180M)
Telbivudine 
(rtM204/I)
Emtricitabine 
(rtV173L, rtL180M, rtM204V/I)
Diagnosis of drug 
resistant HBV Direct sequencing Direct sequencing Direct sequencing
Line probe assay a Clonal analysis Clonal analysis
Clonal analysis RFLP analysis RFLP analysis
RFLP analysis b
a INNO- LiPA DR v2 (Innogenetics, Ghent, Belgium) 
b RFLP: restriction fragment length polymorphismHepatitis Monthly, Winter 2010; 10(1): 42-47
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genotypic  mutations  generally  have  occurred  in 
patients who have developed virologic breakthrough, 
defined as a ≥1 log10 increase in serum HBV DNA 
above nadir, on two or more occasions 1 month 
apart  while  receiving  treatment,  but  genotypic 
mutations can also emerge in patients with persistent 
viraemia and without virologic breakthrough (Fig 1.)
(13). The testing for genotypic resistance can not be 
recommended prior to initiation of therapy unless 
the patient is undergoing treatment for CHB  (20); 
but, despite advances in HBV genotypic resistance 
testing,  an  ETV  mutant  virus  population  can  be 
detected at present, in the absence of ETV treatment 
(in naïve patients and during LAM therapy) (21-25).
Molecular  Assays  in  the  Diagnosis  of  ETV 
Resistance
Four  types  of  molecular  assays  are  available 
for  the  diagnosis  and  managment  of  ETV  drug 
resistance: direct sequencing, line probe assay, clonal 
analysis, and RFLP analysis. Applications of other 
assays are currently more specialized, and their use 
is more limited. The utility of these assays and their 
performance characteristics are defined in Table 2. 
However, the assays more widely used are reviewed 
below.
Direct  Sequencing  of  the  HBV  pol  Gene 
Region
The  reference  method  for  the  detection  of 
resistance-conferring mutations is population-based 
sequencing (ie, a direct sequence analysis of the HBV 
pol  gene).  Genotypic  resistance  assays  use  DNA 
sequencing methods to examine the pol region of the 
HBV genome for recognizable resistance-associated 
mutations (26-28). Sequence analysis is considered the 
gold standard for characterizing HBV DNA isolates 
(29, 30). However, this assay is time-consuming for a 
large number of clinical samples, but is suitable for 
high-throughput screening in a large viral-genome 
region (Table 2). The in-vitro phenotyping of HBV 
mutations  associated  with  antiviral  resistance  in  a 
database  program  such  as  geno2pheno  (http://
coreceptor.bioinf.mpi-inf.)  and  SEQHEPB  tools 
(http://www.seqvirology.com)  (work  in  the  Fasta 
format of the HBV genomic sequence) is a convenient 
approach (31). These tools have great applicability to 
the interpretation of amino - acid substitutions. The 
results between amino acid positions 80 - 250 of 
the HBV pol gene were similarly detected in manual 
and  geno2pheno  tool  analysis.  But,  for  reliable 
predictions the sequences must contain the motif 
“TCCCATCCCATC” starting ateast with codon 159 
in the pol frame (24, 25).
Line-Probe Assay
Line-probe  assays,  using  probes  for  individual 
mutations,  are  specific  and  reproducible  and 
significantly  more  sensitive  in  detecting resistance 
mutations than population-based sequencing. This 
technology is a useful tool for the rapid and accurate 
detection of mutants, which make up as little as 5% of 
Fig 1. Serial changes in serum HBV DNA and ALT levels in association with emergence of antiviral-
resistant HBV mutants. The first manifestation of resistance is the detection of resistance-conferring 
mutations (ie, genotypic resistance) (5, 20). 
ALT: alanine aminotransferase; ULN: upper limit of normal.Hepatitis Monthly, Winter 2010; 10(1): 42-47
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the HBV population, with a sensitivity of 990 copies/
ml at a 95% confidence interval (CI). However, one 
disadvantage of the assay (INNO - LiPA DR v2) is 
the limited scope of the mutations represented in 
the assay, and it only detects known mutations for 
LAM and ADV currently with wild type variants (20, 
22, 30). However, in this technique, recombination of 
genotypes or new mutations cannot be detected (32). 
Periodic updating with new probes specific to novel 
mutations is required, because HBV strains resistant 
to newly developed antiviral drugs have been isolated 
and characterized (Table 2) (33). On the other hand, an 
INNO-LiPA DR v3 that confers resistance to ETV 
therapy has not yet been released as a commercial kit. 
This prototype line-probe assay allows the detection 
of  variants  rtA194T  and  rtI233V  associated  with 
resistance to TDF and ADV, respectively (22). 
Clonal Analysis of HBV Variants
 Minor HBV populations can be identified by large 
- scale cloning and sequencing protocols; however, 
this is laborious and beyond the capacity of clinical 
laboratories. This method, however, is sufficiently 
sensitive  for  the  detection  of  emerging,  resistant 
mutants that are present in low concentrations (34).
For the cloning of the HBV pol region, a 700 bp 
PCR amplification covering the whole HBV pol gene 
can be us ed with the following primers; CLC188 
5’-TCCCCAACCTCCAATCAC-3’ and CLC887 5’-
AAACCCAAAAGACCCACAA-3’ (designed in our 
laboratory). The amplified 700 bp HBV pol region 
can be cloned into a TA vector by using the TOPO-
XL-PCR  cloning  kit  (Invitrogen,  CA,  USA)  and 
the constructs can then be sequenced using the Big 
Dye Terminator v3.1 Cycle sequencing Kit (Applied 
Biosystems, Foster City, CA, USA) in an ABI Prism 
3130  XL  Genetic  Analyser  (Perkin  Elmer,  Foster 
City,  CA,  USA)  according  to  the  manufacturer’s 
instructions (35).
Conclusions
Other powerful technologies are in development, 
including  high-throughput  systems  capable  of 
detecting  polymorphisms  in  the  entire  HBV 
genome using gene chip technology (36). Emerging 
technologies that have not yet penetrated significantly 
Table 2. Comparison of the genotyping methods for diagnosis of drug resistance mutation in hepatitis B virus 
(6, 32, 40).
Direct sequencing Line probe assay Clonal analysis RFLP
Technique Population based sequencing
Differential hybridization on the 
membrane-bound oligonucleotide 
probe 
Cloning of PCR 
product
PCR and restriction 
fragment length 
polymorphism analysis
Sensitivity
Affects sequence context and 
secondary structures in the target, 
minor subpopulations may escape 
detection
Minor subpopulations may escape 
detection
Affects sequence 
context
Minor subpopulations may 
escape detection
Analytic 
sensitivity 10% populations of mutants  5% populations of mutants Can overcome this 
problem 5% populations of mutants
Specificity Single nucleotide mismatch may 
escape detection
New set of specific probes are 
required
Single nucleotide 
mismatch may escape 
detection
Must be designed 
specifically for each mutant 
of interest
Mutation 
detectability
Detects known and potential new 
mutations Only presents mutations Detects known and 
potential new mutations Only known mutations
Usability
Requires sufficient PCR yield 
and perfect purification (works 
consistently only for viral loads of 
over 1E+3 IU/ml)
Requires sufficient PCR yield 
(works consistently for viral loads 
over 990 copies/ml (95% CI) a
Requires large number 
of clones
(works consistently only 
for viral loads of over 
1E+3 IU/ml)
Separate sets of 
endonuclease reactions 
must be designed (works 
consistently only for viral 
loads of over 1E+3 IU/ml)
Cost Expensive but acceptable Expensive Expensive Expensive
Difficulty
Time - consuming, requires 
highly- skilled personnel and 
expensive equipment
Requires highly- skilled personnel
Time – consuming, 
requires highly- 
skilled personnel and 
expensive equipment
Time – consuming, requires 
highly- skilled personnel
Routines  Acceptable Acceptable  unsuitable  unsuitable
Obtaining In - house Commercial kit b In - house In – house
a 990 copies/ml =1.7E + 2 IU/ml in AmpliPrep/Cobas TaqMan 48 HBV test (Roche Diagnostics GmbH, Mannheim, Germany) 
b INNO-LiPA DR v2 (Innogenetics,Ghent, Belgium)Hepatitis Monthly, Winter 2010; 10(1): 42-47
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into diagnostic laboratories may become useful in 
the future.
ETV  resistance,  due  to  variations  at  position 
rt184, rt202, or rt250 alone, seems to have a minor 
impact on ETV susceptibility  (37, 38). However, it 
should be considered that the addition of rtL180M 
and rtM204V induces a more than 70-fold decrease 
in ETV susceptibility; hence, the presence of variants 
resistant to ETV and LAM may be a factor predictive 
of ETV- treatment failure. 
The  monitoring  of  drug-resistant  variants  is 
important for the elucidation of the prevalence and 
the  mechanisms  of  resistance  development  and 
for  the  more  effective  management  of  treatment 
options;  and  genotypic  resistance  testing  may  be 
tailored to the patient’s treatment history and to the 
severity of the disease. 
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